Hepatocellular carcinoma patients with portal vein thrombosis treated with robotic radiosurgery: Interim results of a prospective study

Dutta, Debnarayan; Tatineni, Tushar; Yarlagadda, Sreenija; Gupte, Ajinkya; Reddy, Sruthi K; Madhavan, Radha; Nair, Harikumar; Sasidharan, Ajay; Kannan, R.; Pottayil, S.G.; Holla, Raghavendra; Sudhindran, S.

doi:10.1007/s12664-021-01172-w

“…After EBRT, the overall tumor response rate was reported to be 30-96%, and the median survival time was 7-34.4 months. 681,686,692,[718][719][720][721][722][723][724][725][726][727][728][729][730][731][732][733][734][735][736][737] The response rates var-ied depending on the location of tumors; 30-83% for portal vein tumor invasion and 43-96% for inferior vena cava and right atrium tumor invasion. The median survival period after EBRT in HCC with inferior vena cava and right atrium invasion was 12.1 months and 9.3 months, respectively, which was significantly improved from those reported in previous cohort studies.…”

Section: External Beam Radiation Therapymentioning

confidence: 99%

2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

2022

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the fourth most common cancer among men in South Korea, where the prevalence of chronic hepatitis B infection is high in middle and old age. The current practice guidelines will provide useful and sensible advice for the clinical management of patients with HCC. A total of 49 experts in the fields of hepatology, oncology, surgery, radiology, and radiation oncology from the Korean Liver Cancer Association-National Cancer Center Korea Practice Guideline Revision Committee revised the 2018 Korean guidelines and developed new recommendations that integrate the most up-to-date research findings and expert opinions. These guidelines provide useful information and direction for all clinicians, trainees, and researchers in the diagnosis and treatment of HCC.

show abstract

“…After EBRT, the overall tumor response rate was reported to be 30-96%, and the median survival time was 7-34.4 months. 681,686,692,[718][719][720][721][722][723][724][725][726][727][728][729][730][731][732][733][734][735][736][737] The response rates varied depending on the location of tumors; 30-83% for portal vein tumor invasion and 43-96% for inferior vena cava and right atrium tumor invasion. The median survival period after EBRT in HCC with inferior vena cava and right atrium invasion was 12.1 months and 9.3 months, respec-tively, which was significantly improved from those reported in previous cohort studies.…”

Section: External Beam Radiation Therapymentioning

confidence: 99%

2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

2023

JLC

View full text Add to dashboard Cite

dance of new research findings and therapies for HCC have been presented and published in South Korea and around the globe. As many studies have been conducted, a substantial amount of knowledge have been accumulated on the diagnosis, staging, and treatment of HCC specific to Asia, with the study results showing different clinical behaviors from the West, especially in South Korea; these new research find- KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinomaKorean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea*

show abstract

“…EBRT can be safely performed in advanced HCC with macrovascular invasion. After EBRT, the overall tumor response rate was reported to be 30%–96%, and the median survival time was 7–34.4 months [ 681 686 692 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 ]. The response rates varied depending on the location of tumors; 30%–83% for portal vein tumor invasion and 43%–96% for inferior vena cava and right atrium tumor invasion.…”

Section: External Beam Radiation Therapymentioning

confidence: 99%

2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma

2022

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the fourth most common cancer among men in South Korea, where the prevalence of chronic hepatitis B infection is high in middle and old age. The current practice guidelines will provide useful and sensible advice for the clinical management of patients with HCC. A total of 49 experts in the fields of hepatology, oncology, surgery, radiology, and radiation oncology from the Korean Liver Cancer Association-National Cancer Center Korea Practice Guideline Revision Committee revised the 2018 Korean guidelines and developed new recommendations that integrate the most up-to-date research findings and expert opinions. These guidelines provide useful information and direction for all clinicians, trainees, and researchers in the diagnosis and treatment of HCC.

show abstract

Hepatocellular carcinoma patients with portal vein thrombosis treated with robotic radiosurgery: Interim results of a prospective study

Cited by 12 publications

References 30 publications

2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma

Contact Info

Product

Resources

About